ml-3000 has been researched along with thalidomide in 1 studies
| Studies (ml-3000) | Trials (ml-3000) | Recent Studies (post-2010) (ml-3000) | Studies (thalidomide) | Trials (thalidomide) | Recent Studies (post-2010) (thalidomide) |
|---|---|---|---|---|---|
| 130 | 9 | 56 | 9,789 | 1,385 | 4,342 |
| Protein | Taxonomy | ml-3000 (IC50) | thalidomide (IC50) |
|---|---|---|---|
| Cereblon isoform 4 | Magnetospirillum gryphiswaldense | 7.8 | |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 0.37 | |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 0.5 | |
| DNA damage-binding protein 1 | Homo sapiens (human) | 1.38 | |
| Protein cereblon | Homo sapiens (human) | 1.38 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Evans, R | 1 |
1 other study(ies) available for ml-3000 and thalidomide
| Article | Year |
|---|---|
Anti arthritic drugs--SMi conference: dual inhibitors. 28-29 April 2003, London, UK.
Topics: Acetates; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Arthritis; Clinical Trials as Topic; Complement Activation; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease Models, Animal; Humans; Isoenzymes; Lipoxygenase Inhibitors; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrroles; Thalidomide; Tumor Necrosis Factor-alpha | 2003 |